Bottom line
RYOIX vs BIB: the short answer
RYOIX (Biotechnology Fund) and BIB (ProShares Ultra Nasdaq Biotechnology) share a meaningful slice of their top holdings — about 53% by weight.
But BIB is far broader, holding 267 positions to 74 for RYOIX, so beyond the top names it adds exposure RYOIX doesn't have.
BIB is cheaper at 0.95% vs 1.38% — a difference of $43 a year per $10,000 invested.
Over five years, RYOIX returned +4.0% a year vs −1.0% for BIB.
Updated Nov 19, 2026
RYOIX vs BIB side by side
| RYOIX | BIB | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Guggenheim | ProShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 1.38% | 0.95% |
| Annual cost per $10k | $138 | $95 |
| 10-yr cost on $10k (prospectus) | $1,709 | $1,401 |
| Max front load | — | None |
| 12b-1 fee | 0% | — |
| 1-yr return | +30.7% | +59.3% |
| 5-yr return (annualized) | +4.0% | −1.0% |
| 10-yr return (annualized) | +5.9% | +1.4% |
| Best quarter | +28.3% | +56.2% |
| Worst quarter | −22.5% | −42.7% |
| Net assets (fund) | $136.8M | $73.7M |
| Number of holdings | 74 | 267 |
| Portfolio turnover | 75% | 29% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RYOIX | BIB | Difference |
|---|---|---|---|
| 2025 | +30.7% | +59.3% | −28.6% |
| 2024 | −0.7% | −10.0% | +9.3% |
| 2023 | +6.1% | −1.3% | +7.3% |
| 2022 | −13.1% | −28.6% | +15.6% |
| 2021 | +1.8% | −5.9% | +7.7% |
| 2020 | +22.1% | +39.7% | −17.7% |
| 2019 | +25.0% | +45.5% | −20.5% |
| 2018 | −9.0% | −24.4% | +15.4% |
| 2017 | +29.7% | +40.8% | −11.0% |
| 2016 | −19.5% | −44.2% | +24.7% |
Source: Fund prospectus bar charts
Holdings overlap
17 of RYOIX's top 25 holdings also appear in BIB's top 25.
| Holding | RYOIX | BIB |
|---|---|---|
| Amgen Inc | 5.05% | 4.48% |
| Gilead Sciences Inc | 4.49% | 4.66% |
| Vertex Pharmaceuticals Inc | 4.32% | 4.65% |
| Regeneron Pharmaceuticals Inc | 2.93% | 3.21% |
| Revolution Medicines Inc | 2.48% | 1.57% |
| Alnylam Pharmaceuticals Inc | 2.36% | 2.01% |
| Moderna Inc | 2.15% | 0.94% |
| Biogen Inc | 2.13% | 1.44% |
| Royalty Pharma Plc | 2.01% | 1.20% |
| Illumina Inc | 1.94% | 1.25% |
| Insmed Inc | 1.79% | 1.16% |
| United Therapeutics Corp | 1.72% | 1.22% |
| Guardant Health Inc | 1.72% | 0.85% |
| Roivant Sciences Ltd | 1.66% | 1.08% |
| Incyte Corp | 1.62% | 0.97% |
Source: SEC Form N-PORT
RYOIX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
FAQ
What is the difference between RYOIX and BIB?
Which is cheaper, RYOIX or BIB?
Should I own both RYOIX and BIB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.